-
(4aR,8aR)-5-propyl-2H,4H,4aH,5H,6H,7H,8H,8aH,9H-pyrido[2,3-f]indazole hydrochloride
-
ChemBase ID:
134069
-
Molecular Formular:
C13H22ClN3
-
Molecular Mass:
255.78688
-
Monoisotopic Mass:
255.1502254
-
SMILES and InChIs
SMILES:
CCCN1CCC[C@H]2[C@H]1Cc1c[nH]nc1C2.Cl
Canonical SMILES:
CCCN1CCC[C@H]2[C@H]1Cc1c[nH]nc1C2.Cl
InChI:
InChI=1S/C13H21N3.ClH/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12;/h9-10,13H,2-8H2,1H3,(H,14,15);1H/t10-,13-;/m1./s1
InChIKey:
HJHVRVJTYPKTHX-HTMVYDOJSA-N
-
Cite this record
CBID:134069 http://www.chembase.cn/molecule-134069.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(4aR,8aR)-5-propyl-2H,4H,4aH,5H,6H,7H,8H,8aH,9H-pyrido[2,3-f]indazole hydrochloride
|
|
|
IUPAC Traditional name
|
(4aR,8aR)-5-propyl-2H,4H,4aH,6H,7H,8H,8aH,9H-pyrido[2,3-f]indazole hydrochloride
|
|
|
Synonyms
|
(–)-Quinpirole monohydrochloride
|
trans-(–)-(4aR)-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline monohydrochloride
|
LY-171,555
|
(-)-Quinpirole hydrochloride
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Lipinski's Rule of Five
|
true
|
Acid pKa
|
16.111439
|
H Acceptors
|
2
|
H Donor
|
1
|
LogD (pH = 5.5)
|
-1.3089768
|
LogD (pH = 7.4)
|
-0.31849062
|
Log P
|
2.140967
|
Molar Refractivity
|
66.8137 cm3
|
Polarizability
|
25.464058 Å3
|
Polar Surface Area
|
31.92 Å2
|
Rotatable Bonds
|
2
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
Q102
|
Legal Information Manufactured and sold with the permission of Eli Lilly and Company. Biochem/physiol Actions The putative D2 dopamine receptor agonist quinpirole (LY 171,555) is the most widely used D2 agonist in in vivo and in vitro studies Active enantiomer of (±)-quinpirole. Quinpirole is a dopamine agonist with high affinity for the D2 and D3 dopamine receptor subtypes. Specific [3H]quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 +/- 0.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. The MAOIs clorgyline and Ro 41-1049 were the most potent. MAOIs interact with a novel binding site that is labeled by [3H]quinpirole or that modulates [3H]quinpirole binding. This site may be associated with D2-like dopamine receptors. |
PATENTS
PATENTS
PubChem Patent
Google Patent